Protean BioDiagnostics is thrilled to announce that it has now added same-day molecular testing capability to its CAP CLIA certified molecular laboratories. These assays include key biomarker assessments that include evaluation of KRAS, BRAF, and EGFR for presence of activating mutations that guide therapeutic assessment.
Read MoreProtean BioDiagnostics is one of the first labs to make PD-L1 (SP142) testing available for breast cancer patients. Roche’s VENTANA PD-L1 (SP142) Assay was recently approved as a companion diagnostic assay…
Read More
Protean BioDiagnostics has collaborated with Nucleai to create a new Artificial Intelligence based product, HistoAI, for improving the efficiency and accuracy of Prostate Cancer pathology diagnosis. The AI powered Protean BioDiagnostics service will assist urologists and pathologists by analyzing digital images of whole slide scans of prostate core biopsies to rapidly identify and grade areas of prostatic carcinoma reducing the risk of diagnostic error.
Read More